Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: EU Regulator Skeptical On Vaccine This Year, Takeda Prepares Hyperimmune Alliance

Plus: Fujitsu Pledges Open IP, Zydus Cadila Secure Testing Kit Manufacturing

Executive Summary

EMA leader doesn't share Oxford's optimism, Takeda-led alliance forges ahead with plasma-derived therapy plans, Indian pharma firm Cadila gets into testing kits.

You may also be interested in...



EMA on COVID-19: 'Fast-Tracking Does Not Mean Cutting Corners'

EMA advises caution on COVID-19 vaccine timelines, but says the outlook is more promising for new treatments.  

Coronavirus Update: AstraZeneca To Develop Oxford’s Vaccine, Adaptive Trial Delivers Remdesivir's Good News

AstraZeneca is to develop and distribute Oxford's COVID-19 vaccine candidate in collaboration with Vaccitech. Its developers believe it could be available as early as September.

With Interferon, Zydus Cadila Launches Third Salvo Against COVID-19

Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel